See All Slides - tctmd.com

Slides

Presentation EuroPCR 2018

Anatomical Predictors of Stroke Prevention During Transcatheter Aortic Valve Implantation: The SENTINEL Trial

Presenter: Hasan Jilaihawi

May 23, 2018

Presentation EuroPCR 2018

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

Presenter: David E. Kandzari

May 23, 2018

Presentation EuroPCR 2018

FFR-guided PCI versus Medical Therapy to Reduce Cardiac Death or Myocardial Infarction

Presenter: Frederik M. Zimmermann

May 23, 2018

Presentation EuroPCR 2018

PCI Statement on PCI Treatment for Chronic Coronary Syndrome

Presenter: Michael Haude

May 22, 2018

Presentation EuroPCR 2018

ORBITA: A Physiology-stratified Analysis of the Impact of FFR and iFR on Efficacy of Coronary Angioplasty in Stable Coronary Artery Disease

Presenter: Rasha Al-Lamee

May 22, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

Presentation

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

May 11, 2018

Presentation

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

May 08, 2018

Presentation EAS 2018

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

Presenter: Michelle L. O’Donoghue

May 07, 2018

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Advertisement

Slides

Anatomical Predictors of Stroke Prevention During Transcatheter Aortic Valve Implantation: The SENTINEL Trial

Renal Denervation in the Presence of Antihypertensive Medications: Six-month Results from the Randomized, Blinded, Sham-controlled SPYRAL HTN-ON MED Trial

FFR-guided PCI versus Medical Therapy to Reduce Cardiac Death or Myocardial Infarction

PCI Statement on PCI Treatment for Chronic Coronary Syndrome

ORBITA: A Physiology-stratified Analysis of the Impact of FFR and iFR on Efficacy of Coronary Angioplasty in Stable Coronary Artery Disease

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

Causes and Associated Costs of 30-Day Readmission of TAVR vs SAVR in the US

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content